Efficacy and safety of a novel ClearHemograsper for gastric endoscopic submucosal dissection: A prospective randomized controlled trial.

Sci Rep · 2026 · PMC13099951 · PMID 41807499

Europe PMC DOI

hedged sentence

0.0470

closest p · 0.9× alpha

0.0470

boldest claim

The sentences

did not reach statistical significancep = 0.047actually significant

3.9%), this difference did not reach statistical significance and may be related to the higher prevalence of cardiovascular disease in the ClearHemograsper group (13.8% vs. 3.9%, p = 0.047).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.